Wang Haoyu, Jiang Haitian, Tao Yining, Yang Binghui, Shen Jiakang, Mu Haoran, Wang Chongren, Yang Xiyu, Cai Zhengdong, Li Mu, Sun Wei, Yang Liu, Sun Mengxiong
Department of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Bone Tumor Institution, Shanghai, China.
Front Bioeng Biotechnol. 2024 Nov 13;12:1409988. doi: 10.3389/fbioe.2024.1409988. eCollection 2024.
Osteosarcoma, characterized by high mortality and disability rates, poses a significant challenge due to its complex genetic background and the absence of specific membrane receptors, which hinder effective targeted therapy. Active targeting has emerged as a promising approach to address this issue.
In this study, magnetically driven hydrogel robots (MMHR) were utilized to load and deliver drugs precisely to target sites. The drugs included SCR1481B16, a specific MET inhibitor proven to inhibit MET-driven tumor growth, and Anlotinib. The microrobots were designed to navigate under magnetic guidance, enhancing drug efficacy while minimizing damage to normal tissues.
The study explored the potential of MMHR loaded with SCR1481B16 and Anlotinib in the treatment of Anlotinib-resistant osteosarcoma. The microrobots were successfully designed and produced, demonstrating the ability to deliver drugs precisely to tumor sites. Evaluation of the microrobots showed an enhanced sensitivity of tumors to Anlotinib, providing new insights into the treatment of drug-resistant osteosarcoma.
Tumors overexpressing MET often develop resistance to VEGFR-targeted drugs. The use of SCR1481B16 as a MET inhibitor in combination with Anlotinib, delivered by magnetically driven hydrogel microrobots, offers a novel strategy to overcome this resistance. However, further in-depth research and validation are required before the clinical application of this method can be considered.
In conclusion, magnetically driven hydrogel microrobots loaded with SCR1481B16 provide a promising new strategy for enhancing the sensitivity of Anlotinib-resistant osteosarcoma, bringing hope for future clinical applications in the treatment of this challenging disease.
骨肉瘤具有高死亡率和致残率，因其复杂的遗传背景以及缺乏特异性膜受体，给有效靶向治疗带来了重大挑战，而这阻碍了有效的靶向治疗。主动靶向已成为解决这一问题的一种有前景的方法。
在本研究中，利用磁驱动水凝胶机器人（MMHR）将药物精确加载并递送至靶位点。这些药物包括SCR1481B16，一种已证实可抑制MET驱动的肿瘤生长的特异性MET抑制剂，以及安罗替尼。这些微型机器人被设计成在磁引导下导航，提高药物疗效的同时将对正常组织的损伤降至最低。
该研究探索了负载SCR1481B16和安罗替尼的MMHR在治疗耐安罗替尼骨肉瘤方面的潜力。成功设计并制造出了微型机器人，证明了其将药物精确递送至肿瘤部位的能力。对微型机器人的评估显示肿瘤对安罗替尼的敏感性增强，为耐药骨肉瘤的治疗提供了新的见解。
过表达MET的肿瘤通常会对VEGFR靶向药物产生耐药性。将SCR1481B16作为MET抑制剂与磁驱动水凝胶微型机器人递送的安罗替尼联合使用，提供了一种克服这种耐药性的新策略。然而，在考虑将该方法应用于临床之前，还需要进一步深入研究和验证。
总之，负载SCR1481B16的磁驱动水凝胶微型机器人为提高耐安罗替尼骨肉瘤的敏感性提供了一种有前景的新策略，为治疗这种具有挑战性的疾病的未来临床应用带来了希望。
